Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder

An Oxford-based drug developer has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the footsteps of Neurocrine and Vertex-acquired Crinetics in an endocrinology ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 15 October →